Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2 | Zendy

Esther M. John | Zendy; Barry P. Rosen | Zendy; Joel Moody | Zendy; Tuya Pal | Zendy; Isabel Fan | Zendy; Patricia A. Shaw | Zendy; Harvey A. Risch | Zendy; Thomas A. Sellers | Zendy; Ping Sun | Zendy; Steven A. Narod | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2

Author(s) -

Esther M. John,

Barry P. Rosen,

Joel Moody,

Tuya Pal,

Isabel Fan,

Patricia A. Shaw,

Harvey A. Risch,

Thomas A. Sellers,

Ping Sun,

Steven A. Narod

Publication year - 2012

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/djs494

Subject(s) - ovarian cancer , hazard ratio , medicine , oncology , brca mutation , brca2 protein , serous fluid , cancer , gynecology , survival analysis , survival rate , mutation , ovary , confidence interval , germline mutation , biology , genetics , gene

Studies have suggested that the 5-year survival of women with ovarian cancer and a BRCA1 or BRCA2 mutation is better than expected. We sought to evaluate the impact of carrying a BRCA1 or BRCA2 mutation on long-term survival of women after a diagnosis of invasive ovarian cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research